Will Somers

Title: Innovations by Will Somers in Antibody-Drug Conjugation

Introduction

Will Somers, an accomplished inventor based in Lexington, Massachusetts, holds two notable patents in the field of biopharmaceuticals. His work focuses on advancements that enhance the efficacy and specificity of antibody-drug conjugates (ADCs), significantly contributing to therapeutic solutions in medicine.

Latest Patents

Somers' latest patents encompass groundbreaking methods involving capped and uncapped antibody cysteines. These techniques originate from an innovative antibody production process utilizing mammalian cells. His patents detail how engineered unpaired cysteine residues can be post-translationally modified and capped with specific chemical entities. This ingenuity allows these capped antibodies to undergo further site-specific conjugation, leading to the formation of ADCs or protein drug conjugates. The applications include ADCs created by selectively reducing the cysteine residues of capped antibodies and those formed using chemical handles such as aldehyde, azide, and alkyne biorthogonal groups. Additionally, he explores the production of uncapped antibodies in various media conditions, demonstrating versatility in creating ADCs via direct conjugation to these uncapped antibodies.

Career Highlights

Will Somers is a vital member of Pfizer Corporation, where he applies his innovative prowess to research and development in biopharmaceuticals. His work focuses on creating advanced drug conjugation methods that have the potential to revolutionize cancer treatment strategies.

Collaborations

At Pfizer, Somers collaborates with other talented inventors, including Xiaotian Zhong and Amarnauth Shastrie Prashad. These partnerships foster a creative and productive environment, enabling novel ideas and shared expertise in the field of antibody engineering and drug conjugation.

Conclusion

Through his two patents and collaborative efforts, Will Somers stands at the forefront of innovation in the biopharmaceutical industry. His research on antibody-drug conjugates not only showcases his inventive spirit but also marks a significant advancement in targeted drug delivery, paving the way for enhanced treatment options in oncology.